Recombinant Cynomolgus Monkey CD160 Fc Chimera Protein, CF

When Recombinant Mouse HVEM/TNFRSF14 Fc Chimera (Catalog # 2516-HV) is immobilized at 0.5 μg/mL, Recombinant Cynomolgus Monkey CD160Fc Chimera (Catalog # 10197-CD) binds with an ED50 of 1.5-9 ng/mL.

2 μg/lane of Recombinant Cynomolgus Monkey CD160 Fc Chimera (Catalog # 10197-CD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 40-60 kDa and 80-120 kDa, respectively.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus Monkey CD160 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse HVEM/TNFRSF14 Fc Chimera (Catalog # 2516-HV) is immobilized at 0.5 μg/mL (100 μL/well), the concentration of Recombinant Cynomolgus Monkey CD160 Fc Chimera that produces 50% of the optimal binding response 1.5-9 ng/mL
• Source: Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey CD160 protein
  

  Cynomolgus Monkey CD160 (Ile27-Ser159) Accession # EHH50231	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: EHH50231
• N-terminal Sequence: Ile27
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 41 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 40-60 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus Monkey CD160 Fc Chimera Protein, CF

• BY55
• BY55FLJ46513
• CD160 antigenimmunoglobulin superfamily member
• CD160 molecule
• CD160
• Natural killer cell receptor BY55
• NK1
• NK28

Background

CD160, also known as Natural killer cell receptor BY55, is a GPI-anchored member of the Ig superfamily that is expressed on both cytolytic lymphocytes and some unstimulated CD4⁺ T cells (1-4). In human, it is expressed principally on non-myeloid hematopoietic cells (1, 5-7). It is synthesized as a preproprotein with 181 amino acids including a 24 amino acid (aa) signal sequence, a 135 aa CD160 chain that contain one 96 aa V‑type Ig‑like domain, and a 22 aa propeptide that is cleaved to generate a GPI‑linkage at Ser159. The GPI‑linked CD160 is known to be cleaved by phospholipases and generate an 80 kDa (presumably trimeric) band in SDS‑PAGE (1, 8).  Mature cynomolgus CD160 shares 91% aa sequence identity with human CD160. CD160 is known to bind to HLA-G1, HLA-C, and HVEM (6, 9, 10). Upon engagement, it is reported to associate with CD2 in cis under certain conditions (11, 12). The effects of CD160 ligation appear to be context dependent. When expressed on endothelial cells, CD160 binding to HLA-G1 initiates apoptosis, and thus impacts angiogenesis (6). When expressed on CD56DIM NK cells, CD160 signaling in response to HLA-C binding promotes IFN-gamma, TNF-alpha, and IL-6 secretion (10). When up-regulated on CD4⁺ T cells following activation, CD160 engagement by HVEM (expressed by APC) serves to block a simultaneous LIGHT stimulation of HVEM that promotes receptor expression and cytokine release (1, 2, 7, 13).

1. Cai, G. & G.J. Freeman (2009) Immunol. Rev. 229:244.
2. del Rio, M.L. et al. (2010) J. Leukoc. Biol. 87:223.
3. Maiza, H. et al. (1993) J. Exp. Med. 178:1121.
4. Anumanthan, A. et al. (1998) J. Immunol. 161:2780.
5. Abecassis, S. et al. (2007) J. Invest. Dermatol. 127:1161.
6. Fons, P. et al. (2006) Blood 108:2608.
7. Kaye, J. et al. (2008) Nat. Immunol. 9:122.
8. Giustiniani, J. et al. (2007) J. Immunol. 178:1293.
9. Giustinani, J. et al. (2009) J. Immunol. 182:63.
10. Barakonyi, A. et al. (2004) J. Immunol. 173:5349.
11. Nikolova, M. et al. (2002) Int. Immunol. 14:445.
12. Rabot, M. et al. (2006) Transpl. Immunol. 17:36.
13. Cai, G. et al. (2008) Nat. Immunol. 9:176.

Bioinformatics

• Uniprot:
  • EHH50231()